Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
NCT05828277 · Turning Point Therapeutics, Inc. · PHASE1 · withdrawn · last registry update 2023-09-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient enrollment” | – | Registry record, Turning Point Therapeutics, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NTRK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-09-25Results posted on the registry: Hutchison Medipharma Limited, Fruquintinib (HMPL-013) (NCT03251378)
- 2024-08-21Phase 3 first posted: Nuvation Bio Inc., Taletrectinib + Crizotinib (NCT06564324)
- 2024-08-02Results posted on the registry: Hoffmann-La Roche, entrectinib (NCT04226833)
- 2024-07-23Results posted on the registry: Bayer, Regorafenib, (Stivarga, BAY73-4506) + Nivolumab (Opdivo) (NCT04704154)
- 2024-06-26Results posted on the registry: Wake Forest University Health Sciences, Regorafenib (NCT02581059)
- 2024-06-26Also stopped (terminated): Wake Forest University Health Sciences, Regorafenib (NCT02581059)
- 2024-06-14Results posted on the registry: Hoffmann-La Roche, Alectinib + Vismodegib (NCT03498521)
- 2024-06-07Results posted on the registry: Dompé Farmaceutici S.p.A, Oxervate (NCT05133180)
- 2024-06-05Results posted on the registry: Theseus Pharmaceuticals, THE-630 (NCT05160168)
- 2024-06-05Also stopped (terminated): Theseus Pharmaceuticals, THE-630 (NCT05160168)
- 2024-05-21Results posted on the registry: Academic and Community Cancer Research United, Panitumumab + Regorafenib (NCT03992456)
- 2024-04-29Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + XmAb20717 (NCT05900648)
- 2024-04-09Results posted on the registry: Merck Sharp & Dohme LLC, pembrolizumab + lenvatinib (NCT04776148)
- 2024-04-02Results posted on the registry: Bayer, BAY73-4506 (Regorafenib, Stivarga) (NCT03890731)
- 2024-04-02Results posted on the registry: Turning Point Therapeutics, Inc., TPX-0005 + Trametinib (NCT05071183)
- 2024-04-02Also stopped (terminated): Turning Point Therapeutics, Inc., TPX-0005 + Trametinib (NCT05071183)
- 2024-03-04Also stopped (terminated): OHSU Knight Cancer Institute, Abemaciclib + Abiraterone (NCT03878524)
- 2024-02-23Results posted on the registry: Federation Francophone de Cancerologie Digestive, Regorafenib 160 mg (NCT02788006)
- 2024-02-07Also stopped (terminated): Dana-Farber Cancer Institute, Topical Tazarotene (NCT04071756)
- 2024-01-23Also stopped (withdrawn): OHSU Knight Cancer Institute, Alectinib + Alpelisib (NCT05238831)
- 2024-01-10Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-A1811 + TAS-102, Regorafenib , Fruquintinib (NCT06199973)
- 2024-01-05Results posted on the registry: The University of Texas Health Science Center at San Antonio, Vorinostat + Hydroxychloroquine (NCT02316340)
- 2023-11-22Results posted on the registry: Arkadiusz Z. Dudek, MD, PAC-1 + Entrectinib (NCT04589832)
- 2023-11-22Also stopped (terminated): Arkadiusz Z. Dudek, MD, PAC-1 + Entrectinib (NCT04589832)
- 2023-11-20Phase 3 first posted: Bristol-Myers Squibb, Repotrectinib + Crizotinib (NCT06140836)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision